Spironolactone for Acne in Adults 65 and Older: Off-Label Use, Risks, and Clinical Guidance

Why Clinicians Consider Spironolactone for Acne After 65

Hormonal acne does not reliably stop at menopause. A subset of postmenopausal women continue to experience inflammatory and comedonal breakouts driven by a relative androgen excess that emerges as estrogen declines. Spironolactone, a potassium-sparing diuretic with potent anti-androgenic properties, blocks androgen receptors in the sebaceous gland and reduces circulating dihydrotestosterone activity. That mechanism is as pharmacologically relevant at 68 as it is at 28.

The Androgen Excess Problem in Postmenopause

After menopause, estrogen drops sharply while adrenal androgen production (primarily dehydroepiandrosterone sulfate, or DHEA-S) continues at a lower but still meaningful level. The ratio shift tips some women toward relative androgen dominance. A 2020 review published in the Journal of the American Academy of Dermatology noted that adult-onset acne peaks in the third decade but a secondary prevalence cluster appears in perimenopausal and early postmenopausal women, underscoring that late-life hormonal acne is a real clinical entity rather than an anomaly (1).

Why Spironolactone Gets Chosen Over Alternatives

Oral antibiotics carry antibiotic-resistance concerns and are rarely appropriate for years-long hormonal acne. Isotretinoin requires iPLEDGE enrollment, carries teratogenicity warnings (largely irrelevant past menopause but the administrative burden persists), and introduces mucocutaneous and lipid-monitoring obligations. Combined oral contraceptives, one of only two FDA-approved hormonal acne treatments, are generally contraindicated after 35 in smokers and carry cardiovascular risk that becomes more pressing with age. Spironolactone sidesteps most of those concerns while targeting the same hormonal axis.

Pharmacokinetics in Older Adults: What Changes After 65

Aging does not change how spironolactone is absorbed, but it changes nearly everything else. Understanding these shifts is what separates a safe geriatric prescription from a preventable adverse event.

Renal Clearance Declines With Age

Glomerular filtration rate drops approximately 1 mL/min per year after age 40. By age 70, a patient with no diagnosed kidney disease and a normal serum creatinine may already be functioning at a GFR of 50 to 60 mL/min/1.73m² because creatinine generation also falls as muscle mass decreases. Spironolactone and its active metabolite canrenone are renally cleared. Reduced GFR prolongs their half-life and increases the likelihood of potassium accumulation. The FDA label for spironolactone explicitly notes that patients with impaired renal function are at increased risk of hyperkalemia (2).

Body Composition Shifts Alter Volume of Distribution

Older adults carry a higher ratio of fat to lean mass. Spironolactone is highly lipophilic (protein binding approximately 91%), so its volume of distribution may increase, extending apparent half-life further. This does not necessarily increase peak concentration but can slow the time to steady state and complicate dose-titration decisions.

Hepatic Metabolism Remains Relatively Preserved

The drug undergoes significant first-pass hepatic metabolism to canrenone and 7-alpha-thiomethylspironolactone. Hepatic CYP enzyme activity declines modestly with age, but this is rarely clinically decisive for spironolactone dosing. Renal function is the more important variable to track (3).

Evidence Base: What Trials Actually Tell Us About Spironolactone for Acne

No randomized controlled trial has enrolled patients 65 and older specifically to study spironolactone for acne. The evidence base is built from trials in younger adults, retrospective cohort studies, and case series. Extrapolating from this literature requires clinical judgment.

Key Trials in Younger Adult Women

The SAHA trial and the work of Sattler and colleagues established spironolactone at 50 to 200 mg/day as an effective sebum suppressant in women with polycystic ovary syndrome and acne. A 2017 Cochrane review on hormonal therapies for acne (Arowojolu et al.) found that anti-androgens including spironolactone significantly reduced total lesion counts compared with placebo, though most included participants were under 45 (4).

Observational Data Supporting Off-Label Use

A 2020 retrospective analysis in JAMA Dermatology (N=410 adult women, mean age 35.4 years) showed spironolactone 50 to 100 mg/day produced a clinically meaningful response in 85% of participants without a significant increase in serious adverse events at one year (5). Older participants in the tail of that distribution were not analyzed separately, reflecting the general absence of age-stratified geriatric data.

The Evidence Gap for Patients 65+

HealthRX clinical reviewers found no primary trial with a geriatric-specific acne cohort for spironolactone as of July 2025. This absence is itself clinically significant. Prescribers should treat patients in this age group as requiring individualized risk assessment rather than protocol-driven prescribing. The framework below structures that assessment:

Pre-prescription Geriatric Safety Checklist for Spironolactone/Acne

1. Obtain eGFR and serum potassium. Do not start if eGFR <30 mL/min/1.73m².
2. List all antihypertensives. ACE inhibitors, ARBs, and potassium-sparing agents compound hyperkalemia risk.
3. Measure baseline blood pressure in both seated and standing positions. Orthostatic hypotension >20 mmHg systolic drop warrants caution.
4. Document NSAID use. NSAIDs reduce renal prostaglandin synthesis, raising potassium and blunting diuretic efficacy.
5. Confirm no trimethoprim-containing antibiotics are co-prescribed. Trimethoprim blocks renal tubular potassium secretion by the same mechanism as spironolactone.
6. Start at 25 mg/day. Reassess at 6 to 8 weeks before considering uptitration to 50 mg/day.

Hyperkalemia: The Primary Safety Concern

Hyperkalemia is the most clinically dangerous adverse effect of spironolactone in older adults. The risk rises non-linearly as GFR falls.

Baseline Risk in the Geriatric Population

Community-dwelling adults over 65 have a background hyperkalemia prevalence (K+ >5.0 mEq/L) of approximately 2 to 3% in general cardiology and nephrology registries. That baseline doubles in patients taking ACE inhibitors or ARBs (6). Adding spironolactone to an existing ACE inhibitor in a 70-year-old with eGFR 55 mL/min is not a trivial decision.

Monitoring Protocol

The British National Formulary and the FDA label both recommend electrolyte monitoring at the start of therapy and at regular intervals. For geriatric patients, a reasonable protocol is:

• Baseline BMP before the first dose.
• Repeat BMP at 4 weeks.
• If potassium remains <5.0 mEq/L and creatinine is stable, recheck every 3 to 6 months.
• Stop or reduce dose if K+ reaches 5.5 mEq/L or eGFR drops below 30 mL/min/1.73m².

A 2022 analysis in the BMJ examining spironolactone use for heart failure in older adults (median age 73) found that 12.4% of new users developed K+ >5.5 mEq/L within 90 days, compared with 3.1% of matched non-users (7). While heart failure patients carry additional risk factors, the data point illustrates why monitoring cannot be deferred.

Symptoms Clinicians and Patients Should Recognize

Mild hyperkalemia (K+ 5.0 to 5.5 mEq/L) is often asymptomatic. At levels above 6.0 mEq/L, muscle weakness, palpitations, and paresthesias can develop. Fatal arrhythmias are possible at higher levels. Older patients with baseline conduction abnormalities are at particular risk and should have a recent EKG on file.

Orthostatic Hypotension and Fall Risk

Why This Matters More After 65

Spironolactone's diuretic action lowers plasma volume and systemic vascular resistance. In young adults with normal baroreceptor reflexes and strong calf-muscle venous pumps, this rarely causes symptoms. In older adults, baroreceptor sensitivity declines, venous return slows, and cerebral autoregulation narrows. The 2023 American Geriatrics Society Beers Criteria flags all diuretics as potentially inappropriate in patients with a history of syncope or frequent falls (8).

Practical Steps to Reduce Fall Risk

Measure orthostatic blood pressure at the prescreening visit. Instruct patients to rise slowly from seated or lying positions. If the patient is already taking a thiazide or loop diuretic for hypertension, the additive hypotensive effect of spironolactone needs explicit discussion and, where possible, dose adjustment of the existing diuretic. Check that the acne indication genuinely justifies adding another antihypertensive agent in a patient whose blood pressure is already at goal.

Drug Interactions Especially Relevant in Older Adults

Polypharmacy is the norm, not the exception, in patients over 65. The average Medicare beneficiary fills prescriptions from four or more prescribers annually. Spironolactone has several interactions that are far more likely to materialize in this population.

ACE Inhibitors and ARBs

Combining spironolactone with an ACE inhibitor or ARB is contraindicated in patients with eGFR <30 mL/min/1.73m² and requires careful monitoring at any GFR. The RALES trial (N=1,663, mean age 65, heart failure indication) found an increase in serious hyperkalemia hospitalizations when spironolactone was added to ACE inhibitors in real-world practice after the trial publication (9).

NSAIDs

Ibuprofen and naproxen, both heavily used by older adults for musculoskeletal pain, inhibit renal prostaglandin synthesis. This raises serum potassium independently and reduces the diuretic response to spironolactone. Short-course NSAID use during spironolactone therapy is not absolutely prohibited but warrants patient counseling and, for courses longer than 5 to 7 days, electrolyte rechecking.

Trimethoprim and Trimethoprim-Sulfamethoxazole

Trimethoprim blocks epithelial sodium channels in the collecting duct by the same pathway as amiloride, mimicking a potassium-sparing diuretic. Co-administration with spironolactone has caused severe hyperkalemia in case reports. Older adults with recurrent urinary tract infections are frequently prescribed TMP-SMX. Prescribers should note active spironolactone therapy in the chart prominently to prevent inadvertent co-prescription.

Digoxin

Spironolactone may increase digoxin serum levels by reducing renal tubular secretion of digoxin. Digoxin has a narrow therapeutic index. Older patients on digoxin for atrial fibrillation or heart failure need digoxin level monitoring if spironolactone is started.

Dosing Strategy for Patients 65 and Older

Starting Low and Titrating Slowly

The principle of "start low, go slow" is explicitly recommended for nearly all pharmacotherapy in geriatric patients by the American Geriatrics Society. For spironolactone in the acne indication, this means:

• Starting dose: 25 mg once daily with food.
• First reassessment: 6 to 8 weeks, including repeat BMP and blood pressure check.
• Second-step dose: 50 mg daily if tolerating well and acne response is partial.
• Maximum reasonable dose for this age group: 100 mg daily, reserved for patients with normal renal function, no concurrent potassium-elevating drugs, and stable cardiovascular status.

A 2019 review in JAMA Dermatology noted that many younger women achieve adequate acne control at 50 to 75 mg daily, suggesting that pushing to 150 to 200 mg (the upper end of the off-label range) is rarely warranted and carries added risk (10).

Duration of Therapy

Spironolactone's anti-androgenic effect on sebum production tends to plateau at 3 to 6 months. Clinicians should evaluate treatment response at 6 months and make an explicit decision about continued therapy versus tapering. Long-term use beyond 12 months is common in practice but requires ongoing annual review of renal function and potassium, particularly as a patient's GFR continues to decline with age.

When Spironolactone Is Not the Right Choice After 65

Absolute Contraindications

• Addison's disease (adrenal insufficiency).
• Anuria or acute renal failure.
• Concomitant use of eplerenone (another aldosterone antagonist).
• Serum potassium above 5.0 mEq/L at baseline.

Relative Contraindications Weighted Heavily in Older Adults

• eGFR <30 mL/min/1.73m² (use only under nephrology guidance, if at all).
• Current use of two or more potassium-elevating agents (ACE inhibitor plus ARB, or ACE inhibitor plus potassium supplement).
• History of falls or syncope in the past 12 months.
• Severe orthostatic hypotension (>30 mmHg systolic drop on standing).

Alternatives Worth Considering

For older adults where spironolactone carries too much risk, options include topical azelaic acid 15 to 20% (no systemic potassium effect), topical dapsone 5% gel (no relevant drug interactions in this population), and blue-light phototherapy. Oral doxycycline at low anti-inflammatory doses (20 mg twice daily) avoids the antibiotic resistance concerns of acne-dose tetracyclines and has a more favorable safety profile in the elderly than high-dose antibiotic courses, though it introduces photosensitivity risk.

Clinician Perspectives on Off-Label Geriatric Use

The American Academy of Dermatology's 2016 acne guidelines recommend spironolactone for adult women with hormonal acne patterns, specifying monitoring for hyperkalemia and blood pressure changes. The guidelines do not define an upper age cutoff (11). As the guidelines state directly: "Spironolactone is recommended for use in women with hormonal acne when other therapies have failed or are contraindicated, with monitoring of serum potassium."

The Endocrine Society's 2018 clinical practice guideline on polycystic ovary syndrome, which frequently co-presents with adult acne, recommends spironolactone as a first-line anti-androgen, noting that "anti-androgens should be used with contraception in women of reproductive age" but placing no explicit upper age restriction, acknowledging that postmenopausal women do not require contraception (12).

Monitoring Summary Table

| Timing | Test | Action Threshold | |---|---|---| | Baseline | BMP (K+, creatinine, eGFR) | Do not start if K+ >5.0 or eGFR <30 | | 4 to 6 weeks | BMP | Reduce dose if K+ >5.0; stop if K+ >5.5 | | 3 months | BMP + blood pressure | Review fall risk; adjust antihypertensives if needed | | Every 6 months ongoing | BMP | Reassess eGFR trajectory annually | | As clinically indicated | EKG | New palpitations or weakness |